The CDMO’s Plants 1 through 4 remained stable while providing a “solid” operational base last year, the company said, with Plant 5 to begin contributing to revenue in 2026.
The collaboration, which includes Merck Sharp & Dohme and Hilleman Laboratories, will focus on improving process yield and storage to support scalable vaccine production.
